McKesson Corporation (MCK) Q3 2025 Earnings Call Transcript
McKesson Corporation. (NYSE:MCK ) Q3 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Rachel Rodriguez - VP of Investor Relations Brian Tyler - Chief Executive Officer Britt Vitalone - Executive Vice President and Chief Financial Officer Conference Call Participants Eric Percher - Nephron Research Kevin Caliendo - UBS Allen Lutz - Bank of America Brian Tanquilut - Jefferies Lisa Gill - JPMorgan Stephen Baxter - Wells Fargo Erin Wright - Morgan Stanley George Hill - Deutsche Bank Daniel Grosslight - Citi Operator Welcome to McKesson's Third Quarter Fiscal 2025 Earnings Conference Call.
Here's What Key Metrics Tell Us About McKesson (MCK) Q3 Earnings
While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
McKesson (MCK) Q3 Earnings and Revenues Miss Estimates
McKesson (MCK) came out with quarterly earnings of $8.03 per share, missing the Zacks Consensus Estimate of $8.04 per share. This compares to earnings of $7.74 per share a year ago.
McKesson misses third-quarter revenue estimates
Drug distributor McKesson missed estimates for third-quarter revenue on Wednesday, hurt by less-than-expected sales in its U.S. pharmaceutical segment, which includes branded and specialty drugs.
McKesson Exceeds EPS, Q3 Profit Surges
Healthcare distribution and services specialist McKesson (MCK 0.59%) reported mixed financial results for fiscal 2025's third quarter on Wednesday, Feb. 5. McKesson beat earnings expectations with an adjusted EPS of $8.03, coming in just ahead of the projected $8.01.
McKesson Stock May Rise With PRISM Vision Holdings Acquisition
MCK is set to acquire a controlling stake in PRISM Vision Holdings, aiming to expand its specialty care capabilities and strengthen its leadership in eye health solutions across the United States.
MCK Stock Before Q3 Earnings: A Smart Buy or Risky Investment?
McKesson's third-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
McKesson (MCK) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, McKesson (MCK) stood at $594.75, denoting a -1.63% change from the preceding trading day.
Gear Up for McKesson (MCK) Q3 Earnings: Wall Street Estimates for Key Metrics
Evaluate the expected performance of McKesson (MCK) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson (MCK) Stock Drops Despite Market Gains: Important Facts to Note
McKesson (MCK) closed at $602.95 in the latest trading session, marking a -0.24% move from the prior day.
McKesson (MCK) Stock Declines While Market Improves: Some Information for Investors
McKesson (MCK) closed at $586.08 in the latest trading session, marking a -1.1% move from the prior day.
